To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the authority to grant certain exemptions, and for other purposes.

This bill reauthorizes through FY2027 (1) the Humanitarian Device Exemption Program (a specialized regulatory pathway for medical devices used to treat or diagnose diseases or conditions that affect no more than 8,000 individuals), and (2) the Pediatric Device Consortia Grants Program (a program that supports the development of medical devices for pediatric patients through nonprofit consortia).

Bill 117 hr 7679, also known as the "FDA Exemptions Reauthorization Act," aims to amend the Federal Food, Drug, and Cosmetic Act in order to extend the authority to grant certain exemptions. The bill seeks to reauthorize the ability to grant exemptions for specific products or substances that may not meet all the requirements outlined in the Act.

The main purpose of this bill is to ensure that the Food and Drug Administration (FDA) has the flexibility to grant exemptions when necessary, in order to promote innovation and access to new products while still maintaining safety and efficacy standards. This reauthorization is important for industries that rely on exemptions to bring new products to market, such as medical devices or certain food additives.

Overall, the bill is focused on balancing the need for regulatory oversight with the need for flexibility and innovation in the marketplace. It is intended to support the FDA in its mission to protect public health while also fostering growth and development in industries regulated by the Act.